Nomograms Help Predict Survival Outcomes in Osteosarcoma Patients
A retrospective study was used to develop nomograms predictive of both metastasis-free and overall survival for patients with nonmetastatic osteosarcoma.
NF1 Mutation Present in Many BRAF, NRAS Wildtype Melanomas
Whole-exome sequencing found that mutations of the NF1 gene are an important driver mutation in melanoma, and the third most frequently mutated gene.
Carbonyl Compounds in Breath Could Help Diagnose Lung Cancer
Six carbonyl compounds in exhaled breath can effectively discriminate between lung cancer patients and healthy patients, says a new study.
Carfilzomib Gets Expanded FDA Approval for Multiple Myeloma
The FDA approved the proteasome inhibitor carfilzomib for the treatment of multiple myeloma, when used in combination with lenalidomide and dexamethasone.
Gemcitabine With EBRT Shows Promise in Soft-Tissue Sarcoma
In a phase I study, gemcitabine given concurrently with fixed-dose EBRT showed promising results following surgery in patients with high-risk soft-tissue sarcoma.
Younger CRC Patients Often Have Hereditary Syndromes
Patients diagnosed with colorectal cancer at younger ages are more likely to have an underlying hereditary syndrome than older patients, according to a new study.
Circulating DNA Offers Real-Time Genotype Information in CRC
The use of BEAMing technology on circulating DNA to identify multiple mutations in real time could help guide treatment in colorectal cancer patients.
Tivantinib With Erlotinib Fails to Improve OS in NSCLC
Adding tivantinib to erlotinib improved progression-free survival but not overall survival in patients with previously treated non-small-cell lung cancer.
Immunotherapy Granted Orphan Drug Status for Ovarian Cancer
The FDA has granted Orphan Drug Designation to the immunotherapy DPX-Survivac, which is in development for the treatment of ovarian cancer.
Long-Term Data Highlights Nilotinib Efficacy, Cardiovascular Effects
Long-term follow-up of a phase II study shows that nilotinib is highly effective in treating chronic phase CML as a first-line therapy, though with relatively common cardiovascular toxicity associated with treatment.
Radiofrequency Ablation an Option for Inoperable Early-Stage NSCLC
The use of CT-guided radiofrequency ablation is well tolerated and effective among patients with inoperable stage IA non-small-cell lung cancer.
Dasatinib, Imatinib, Associated With Differing Mutation Patterns in CML
Patients with CML undergoing treatment with dasatinib had a narrower spectrum of mutations in BCR-ABL1 compared to those treated with imatinib.
De-escalation of Bone-Targeting Agents Appears Safe
A new meta-analysis suggests that de-escalation of bone-targeted agents is a safe strategy in breast cancer patients with bone metastases.
Post-Op RT Improves Survival in Incompletely Resected NSCLC
Use of post-operative radiotherapy was associated with better overall survival in patients with incompletely resected stage II/III non-small-cell lung cancer.
Majority of Lung, Colorectal Cancer Patients Believe Surgery Curative
Large proportions of lung and colorectal cancer patients believe that surgery will cure their cancer, according to results of a new population-based study.
TS Expression Could Guide Treatment in Nonsquamous NSCLC
The combination of pemetrexed/cisplatin was superior to gemcitabine/cisplatin in non-squamous NSCLC patients negative for the thymidylate synthase enzyme.
Nodal Metastases Linked With Decreased Survival Even in Younger Thyroid Cancer Patients
The presence of cervical lymph node metastases was associated with compromised survival even in younger patients with papillary thyroid cancer.
TDM-1 Better Than Trastuzumab in HER2-, HR-Positive Breast Cancer
Neoadjuvant TDM-1 was shown to be effective in treating HER2-positive, HR-positive breast cancer compared with trastuzumab, with or without endocrine therapy.
Alectinib Promising in ALK-Positive Advanced NSCLC
Alectinib yielded good response rates and was very well tolerated in a phase II trial of patients with advanced, ALK-positive non–small-cell lung cancer.
Neoadjuvant Pertuzumab Adds Benefit in HER2-Positive Breast Cancer
The addition of pertuzumab to trastuzumab and docetaxel offers significant improvement over other options in patients with HER2-positive breast cancer.
Patient Beliefs Tied to Suboptimal Adherence to CML Medications
Beliefs regarding medication for chronic myeloid leukemia (CML) are strongly associated with suboptimal treatment adherence, according to a new study.
Transcriptional Inhibitor With Doxorubicin Shows Promise in SCLC
A phase I study showed that transcriptional inhibitor PM01183 with doxorubicin induced responses in patients with small-cell lung cancer.
Long-Term Data Show Ponatinib Effective, With Thrombotic Risk in CML
Ponatinib demonstrates continuing clinical activity in chronic-phase chronic myeloid leukemia patients who failed prior treatment with other TKIs.
Adding Obinutuzumab Improves PFS in Refractory NHL
Obinutuzumab in combination with bendamustine followed by obinutuzumab maintenance improved PFS over bendamustine monotherapy in patients with refractory non-Hodgkin lymphoma.
AML Vaccine Proves Feasible, Potentially Beneficial
A vaccine known as AST-VAC1 was successfully produced from most patients in a phase II trial of patients with acute myeloid leukemia.
Cognitive Impairment in Pediatric ALL Survivors Even Without Brain RT
Even in the absence of cranial radiation therapy, survivors of childhood acute lymphoblastic leukemia (ALL) have decreased neurocognitive function years later.
Nedaplatin Improves on Cisplatin in Advanced Lung SCC
The platinum compound nedaplatin in combination with docetaxel improved outcomes over cisplatin and docetaxel in advanced squamous cell carcinoma of the lung.
Ibrutinib Improves on Standard of Care in CLL/SLL
A trial found that ibrutinib in combination with bendamustine and rituximab is superior to standard of care in patients with previously treated CLL/SLL.
New FLT3 Inhibitor Improves Responses in Relapsed AML
An inhibitor of FLT3 known as ASP2215 showed good clinical activity in FLT3-mutated patients with relapsed or refractory acute myeloid leukemia (AML).
LUX-Lung 8: Afatinib Tops Erlotinib in Squamous NSCLC
Data from the LUX-Lung 8 trial showed afatinib outperformed erlotinib with regard to both progression-free and overall survival in squamous cell lung cancer.